| Literature DB >> 20307718 |
Frans J Smiers1, Lakshmanan Krishnamurti, Guido Lucarelli.
Abstract
Despite improvements in the management of thalassemia major and sickle cell disease, treatment complications are frequent and life expectancy remains diminished for these patients. Hematopoietic stem cell transplantation (HSCT) is the only curative option currently available. Existing results for HSCT in patients with hemoglobinopathy are excellent and still improving. New conditioning regimens are being used to reduce treatment-related toxicity and new donor pools accessed to increase the number of patients who can undergo HSCT. Copyright 2010 Elsevier Inc. All rights reserved.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20307718 DOI： 10.1016/j.pcl.2010.01.003
Source DB: PubMed Journal: Pediatr Clin North Am ISSN： 0031-3955 Impact factor: 3.278